Synthesis of Micheliolide Derivatives and Their Activities against AML Progenitor Cells

Wei-Wei Ma 1, Qian-Qian Shi 2, Ya-Hui Ding 3, Jing Long 1, Quan Zhang 1,* and Yue Chen 1,*

1 College of Pharmacy, the State Key Laboratory of Elemento-Organic Chemistry, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China; E-Mails: mww23@126.com (W.-W.M.); jingtufeii@163.com (J.L.)
2 College of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China; E-Mail: shiqian2634@126.com
3 Accendatech Co., Ltd, Tianjin 300384, China; E-Mail: chuanshuo2200@sina.com

* Authors to whom correspondence should be addressed; E-Mails: zhangquan612@163.com (Q.Z.); yuechen@nankai.edu.cn (Y.C.); Tel./Fax: +86-22-2350-8090 (Y.C.).

Received: 27 April 2013; in revised form: 15 May 2013 / Accepted: 16 May 2013 / Published: 21 May 2013

Abstract: Micheliolide (MCL) derivatives with etherification or esterification of the hydroxyl group at the C4 position were synthesized and evaluated for their activities against different acute myelogenous leukemia (AML) cell lines. These derivatives demonstrated comparable activities against AML cell lines HL-60 and doxorubicin resistant cell line HL-60/A. As to multi-drug resistant AML progenitor cells KG-1a, MCL and some of its derivatives maintained significant activities, and only 1.1–2.7 fold activity reductions were observed when compared with the activities against HL-60, while doxorubicin showed 20-fold activity reduction. Our study demonstrated that the C4 hydroxyl group of MCL might not only be a suitable position for structural modifications, but also a starting point for the design of appropriate molecular probes to explore the specific targets in the progenitor cell line KG-1a.

Keywords: leukemia progenitor cell; micheliolide; KG-1a; derivative; synthesis
1. Introduction

Leukemia is one of the most aggressive adult cancers, as well as the most prevalent childhood cancer. Leukemia is a cancer of the hematological system and can be divided into a diversity of unique malignancies based on the onset of the disease as well as the specific cell lineages involved [1]. Acute myelogenous leukemia (AML) is a malignant disease characterized by an aberrant accumulation of immature myeloid hematopoietic cells. Multi-drug resistance and relapse are the main difficulties in the treatment of most AML patients. Recent studies have indicated that the drug resistance and relapse of AML arises from a rare population of leukemic stem cells (LSCs), and new therapeutics targeting LSC are urgently needed [2–4]. KG-1a cells are a type of short-term CD34+ hematopoietic progenitor cell line, and contain leukemia stem-like cells characterized by the CD34+CD38− biomaker [5]; in some cases, the leukemic stem-like cells comprise about 50% of the total KG-1a cells [6]. KG-1a cells exhibit high p-glycoprotein-mediated drug efflux capacity and a high level of anthracycline resistance [2]. Thus, KG-1a cells present a relevant cellular model for leukemic stem cells research.

Parthenolide (PTL, Figure 1), a naturally occurring germacrane sesquiterpene lactone, was identified as a promising agent targeting AML stem cell populations [7,8]. DMAPT, the water-soluble dimethylamino Michael adduct of PTL, has entered clinical trials in the United Kingdom for the treatment of AML, ALL, and CLL [9,10]. Recently, we reported that guaianolide sesquiterpene lactones could selectively inhibit AML stem and progenitor cells, and micheliolide (MCL, 1, Figure 1) was identified as the lead compound for reducing the proportion of AML stem cells (CD34+CD38−) in primary AML cells. Moreover, the dimethylamino Michael adduct of MCL, DMAMCL, demonstrated remarkable therapeutic efficacy in the AML NOD/SCID mice models, and very low acute toxicity in mice [11]. In view of the high therapeutic potential of MCL and DMAMCL, we were interested in further investigation of the structure-activity relationships of MCL. MCL, a guaianolide sesquiterpene lactone [12] isolated from Michelia compressa [13] and Michelia champaca [14], was also prepared by semisynthesis from parthenolide in 90% yield [15]. Thus, with MCL as the starting material, we synthesized a series of MCL derivatives and investigated their biological activities as potential anti-AML progenitor agents.

Figure 1. Structure of parthenolide (PTL) and micheliolide (MCL, 1).

2. Results and Discussion

2.1. Chemistry

It has been proposed that a parent molecule could be made more cytotoxic by increasing the lipophilic character and/or by adding alkylating groups [16,17]. The presence of the free hydroxyl
group at C4 position allowed us to prepare ether or ester derivatives of compound 1. As shown in Scheme 1, compound 1 was treated with CH₃I, benzyl bromide, or CH₃OCH₂Cl to provide etherified derivatives 2, 3 and 4 respectively. Reaction of compound 1 with different acyl chloride in the presence of 4-dimethylaminopyridine (DMAP) or NaH gave compounds 5–10, 13–16, and 18–22 in low to moderate yields (14%–78%). Treatment of compound 1 with carboxylic acids in the presence of N,N'-dicyclohexylcarbodiimide (DCC) and DMAP afforded compounds 11 and 12. Synthesis of compound 17 was achieved via Sc(OTf)₃ catalyzed reaction of compound 1 and 5-bromopentanoic acid in the presence of diisopropylcarbodiimide (DIPC) and DMAP [18]. The 1,3-dipolar cycloaddition with compound 22 and 6-azidohexan-1-ol in the presence of CuSO₄·5H₂O and sodium ascorbate afforded compound 23 (Scheme 2).

**Scheme 1.** Synthesis of compounds 2–22.

Reagents and conditions: (a) for compound 2: CH₃I, NaH, THF, rt, 36%; for compound 3: CH₃OCH₂Cl, NaH, THF, rt, 64%; for compound 4: benzyl bromide, NaH, THF, rt, 40%; (b) for compounds 5, 6, 9, 10, 13, and 18–22: RCl, Et₃N, DMAP, CH₂Cl₂, rt, 14%–78%; for compounds 7, 8, and 14–16: RCl, NaH, THF, rt, 21%–56%; for compounds 11 and 12: RCOOH, EDCI, DMAP, CH₂Cl₂, rt, 48%–53%; for compound 17: RCOOH, Sc(OTf)₃, DIPC, DMAP, CH₂Cl₂, rt, 26%.

**Scheme 2.** Synthesis of compound 23.

2.2. Activities against AML Cell Lines

This series of MCL derivatives was then tested for activities against cultured AML cell line HL-60 and doxorubicin-resistant cell line HL-60/A. Doxorubicin (DOX), an anti-AML drug in clinical application) was applied as positive control [11]. The results are summarized in Table 1.

Doxorubicin demonstrated over 100-fold reduction against HL-60/A (IC₅₀ = 6.7 μM) vs. HL-60 (IC₅₀ = 0.05 μM). The parent compound 1 showed comparable inhibitory potency to HL-60/A (6.2 μM) and HL-60 (IC₅₀ = 5.5 μM) [11]. For the etherified compound 2, masking of the C4-OH with a methyl group also resulted in comparable activities against HL-60/A (IC₅₀ = 10.2 μM) and HL-60 (IC₅₀ = 9.9 μM). Replacement of the methyl moiety with a more bulky substituent (compound 3) slightly reduced the anti-AML activity, and potent inhibitory activities against HL-60 and HL-60/A.
were found to be retained in the methoxymethyl derivative (compound 4) with IC₅₀ values of 3.5 μM and 6.2 μM against HL-60 and HL-60/A, respectively.

**Table 1.** Inhibitory effects of compounds 1–23 on HL-60, HL-60/A, and KG-1a cell lines.

| Compounds | R          | IC₅₀ b (μM) | Times f |
|-----------|------------|-------------|---------|
|           |            | HL-60 c | HL-60/A d | KG-1a e |
| DOX g     | -          | 0.05 ± 0.01 | 6.7 ± 1.1 | 1.0 ± 0.3 | 20 |
| 1 (MCL)   | H          | 5.5 ± 1.4 | 6.2 ± 2.2 | 13.4 ± 1.0 | 2.4 |
| 2 b       | CH₃        | 9.9 ± 0.9 | 10.2 ± 0.1 | - | - |
| 3         |            | 16.7 ± 0.8 | 18.9 ± 4.6 | 13.4 ± 1.0 | 2.4 |
| 4         |            | 3.5 ± 0.6 | 6.2 ± 0.4 | - | - |
| 5         |            | 12.0 ± 3.2 | 8.3 ± 2.3 | - | - |
| 6         |            | 10.0 ± 0.6 | 15.6 ± 0.1 | - | - |
| 7         |            | 11.8 ± 1.4 | 14.2 ± 2.2 | 15.9 ± 0.9 | 1.3 |
| 8         |            | 13.7 ± 1.7 | 22.0 ± 1.4 | - | - |
| 9         |            | 10.1 ± 2.2 | 12.5 ± 0.3 | 11.5 ± 1.4 | 1.1 |
| 10        |            | 15.7 ± 1.7 | 15.1 ± 4.2 | - | - |
| 11        |            | 16.1 ± 3.1 | 29.7 ± 5.9 | - | - |
| 12        |            | 12.4 ± 0.2 | 18.0 ± 1.0 | - | - |
| 13        |            | 7.2 ± 2.7 | 15.7 ± 3.0 | 19.4 ± 4.2 | 2.7 |
| 14        |            | 16.1 ± 1.9 | 20.3 ± 5.7 | - | - |
| 15        |            | 18.0 ± 3.4 | 20.0 ± 3.2 | - | - |
| 16        |            | 2.8 ± 0.9 | 4.2 ± 0.2 | 7.5 ± 0.9 | 2.7 |
| 17        |            | 13.7 ± 2.6 | 16.7 ± 1.0 | - | - |
| 18        |            | 7.4 ± 1.6 | 8.5 ± 1.8 | 10.4 ± 2.3 | 1.4 |
The esterified subseries of compounds 5–13, 24, 23 have different substitution patterns on the C4 position. As shown in Table 1, these compounds generally exhibited slightly reduced or comparable activities against HL-60 (IC$_{50}$ = 7.2–16.1 µM) and HL-60/A (IC$_{50}$ = 8.3–29.7 µM). This result indicates that a range of substituents with different lipophilic, electronic, and steric characters is tolerated at the C4 position of compound 1. The most potent compound in this subseries was compound 13, with IC$_{50}$ values of 7.2 µM and 15.7 µM against HL-60 and HL-60/A, respectively, which was comparable to that of compound 1.

As to the haloacylated subseries of compounds 14–17, compound 16 exhibited high activities against HL-60 (IC$_{50}$ = 2.8 µM) and HL-60/A (IC$_{50}$ = 4.2 µM), suggesting additional alkylating groups appear to enhance anti-AML activity (cf. compound 16 to compound 1). However, compounds 14, 15, and 17 showed decreased activity, which indicates that there is an optimum property, number, and position for the substitution of α halogen atoms. When a conjugated ester group (i.e., compounds 18–21) was added to the compound 1 to supply additional Michael receptors, the anti-AML activities were mainly retained. Moreover, the gradation of activities exhibited by compounds 18–21 demonstrated that along with the increment of the steric hindrance of the conjugated ester, the activities against HL-60 were declining.

The relatively potent compounds 7, 9, 13, 16, 18, and 22 were further screened to obtain their inhibitory activities against AML KG-1a progenitor cells (Table 1). Compared with MCL, these compounds maintained comparable activities against the KG-1a cell line (IC$_{50}$ = 7.5–19.4 µM). The most potent compound was compound 16 (IC$_{50}$ = 7.5 µM), which was slightly more potent than MCL (IC$_{50}$ = 13.4 µM). Moreover, MCL and derivatives 7, 9, 13, 16, 18, and 22 maintained significant activities, and only 1.1–2.7 fold activity reductions were observed when compared with their activities against HL-60, while doxorubicin demonstrated over 20-fold reduction against KG-1a (IC$_{50}$ = 1.0 µM) vs. HL-60 (IC$_{50}$ = 0.05 µM).

### Table 1. Cont.

| Compounds | R | IC$_{50}$ (µM) | Times $^f$ |
|-----------|---|----------------|-----------|
|           |   | HL-60 $^e$     | HL-60/A $^d$ | KG-1a $^e$ |
| 19        |   | 12.6 ± 0.2     | 11.7 ± 2.2 | -           |
| 20        |   | 13.1 ± 1.2     | 17.6 ± 4.6 | -           |
| 21        |   | 15.1 ± 1.9     | 14.7 ± 1.9 | -           |
| 22        |   | 8.1 ± 1.4      | 10.8 ± 1.9 | 10.5 ± 0.6  | 1.3 |
| 23        |   | 16.4 ± 4.3     | 29.0 ± 1.4 | -           |

$^a$ All values are the mean of three independent experiments; $^b$ IC$_{50}$: 50% cytotoxic concentration; $^c$ HL-60: cultured AML cell line; $^d$ HL-60/A: doxorubicin-resistant cell line; $^e$ KG-1a: AML progenitor cell line; $^f$ Ratio of the IC$_{50}$ value for KG1a compared to the IC$_{50}$ value for HL-60; $^g$ DOX: doxorubicin, a clinically popular anti-AML agent used as a positive control; $^h$ Data from reference [11].
3. Experimental

3.1. General

The starting material micheliolide (MCL, 1) was obtained from Accendatech Co., Ltd. (Tianjin, China). The solvents used were purified and dried according to common procedures. $^1$H-NMR (400 MHz) and $^{13}$C-NMR spectra (100 MHz) were obtained on a Bruker AV 400 instrument using CDCl$_3$ as the solvent. Chemical shifts are reported in parts per million (ppm) relative to either a tetramethylsilane internal standard or solvent signals. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br. = broad, m = multiplet), coupling constants and integration. High-resolution mass spectra were recorded using an Agilent 6520 Q-TOF LC/MS instrument by the ESI-FTICR technique.

3.2. Product Synthesis and Characterization

**General Procedure for the Synthesis of Compounds 5, 6, 9, 10, 13, and 18–22**

To a solution of MCL (24.8 mg, 0.1 mmol), Et$_3$N (121.2 mg, 1.2 mmol), and DMAP (12.2 mg, 0.1 mmol) in anhydrous CH$_2$Cl$_2$ (1 mL) was added appropriate acyl chloride (1.0 mmol) at 0 °C. The resulting mixture was stirred at room temperature until the starting material disappeared on the TLC. The reaction mixture was diluted with water (2 mL), extracted with CH$_2$Cl$_2$ (5 mL × 2). The organic layer was successively washed with saturated citric acid (5 mL × 3), NaHCO$_3$ (5 mL × 3), and brine (5 mL × 3), and then dried over anhydrous Na$_2$SO$_4$, concentrated under reduced pressure to give a crude residue, which was purified by silica gel column chromatography to afford the product.

**(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl acetate (5):** yield 63%, white amorphous powder; $^1$H-NMR $\delta$ 6.13 (1H, d, $J = 3.1$ Hz), 5.40 (1H, d, $J = 2.8$ Hz), 3.72 (1H, t, $J = 10.2$ Hz), 3.08 (1H, d, $J = 10.1$ Hz), 2.65–2.59 (1H, m), 2.41–2.35 (2H, m), 2.21–2.13 (4H, m), 1.97 (3H, s), 1.91–1.83 (1H, m), 1.65 (3H, s), 1.48 (3H, s); $^{13}$C-NMR $\delta$ 169.6, 169.3, 138.4, 130.6, 117.8, 87.7, 82.0, 55.6, 49.1, 35.4, 33.9, 29.4, 24.9, 23.2, 21.5, 17.8; HRMS (ESI) for C$_{17}$H$_{23}$O$_4$, calcd 291.1596, found 291.1593.

**(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl propionate (6):** yield 70%, white amorphous powder; $^1$H-NMR $\delta$ 6.20 (1H, d, $J = 3.1$ Hz), 5.47 (1H, d, $J = 2.8$ Hz), 3.79 (1H, t, $J = 10.1$ Hz), 3.13 (1H, d, $J = 10.2$ Hz), 2.71–2.66 (1H, m), 2.49–2.42 (2H, m), 2.38–2.30 (2H, m), 2.28–2.26 (4H, m), 2.11–2.08 (1H, dd, $J = 13.8, 1.8$ Hz), 1.97–1.89 (1H, m), 1.72 (3H, s), 1.57 (6H, d, $J = 9.0$ Hz); $^{13}$C-NMR $\delta$ 173.8, 170.2, 139.5, 131.5, 130.4, 118.6, 88.4, 83.0, 56.6, 50.1, 36.5, 34.9, 30.4, 28.7, 25.9, 24.1, 18.8, 9.1; HRMS (ESI) for C$_{18}$H$_{28}$NO$_4$, calcd 322.2018, found 322.2013.

**(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 3-methylbutanoate (9):** yield 48%, white amorphous powder; $^1$H-NMR $\delta$ 6.19 (1H, d, $J = 3.2$ Hz), 5.46 (1H, d, $J = 2.9$ Hz), 3.78 (1H, t, $J = 10.1$ Hz), 3.13 (1H, d, $J = 10.1$ Hz), 2.71–2.66 (1H, m), 2.50–2.42 (2H, m), 2.28–2.26 (3H, m), 2.20–2.07 (4H, m), 1.97–1.89 (1H, m), 1.72–1.69 (4H, m), 1.56
(3H, s), 0.97 (6H, d, J = 5.9 Hz); 13C-NMR δ 172.7, 170.2, 139.5, 131.6, 130.5, 118.7, 88.5, 83.0, 56.8, 50.2, 44.6, 36.6, 35.0, 30.5, 25.9, 25.8, 24.2, 22.4, 22.3, 18.8; HRMS (ESI) for C20H32NO4, calcd 350.2331, found 350.2326.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 3-phenylpropanoate (10): yield 24%, white amorphous powder; 1H-NMR δ 7.32–7.18 (5H, m), 6.22 (1H, d, J = 3.3 Hz), 5.49 (1H, d, J = 3.0 Hz), 3.80 (1H, t, J = 10.1 Hz), 3.12 (1H, d, J = 10.1 Hz), 2.99 (2H, t, J = 7.9 Hz), 2.73–2.59 (3H, m), 2.49–2.43 (2H, m), 2.30–2.28 (3H, m), 2.14–2.10 (1H, dd, J = 13.8, 2.3 Hz), 1.96–1.87 (1H, m), 1.74 (3H, s), 1.65 (1H, s), 1.56 (3H, s); 13C-NMR δ 172.3, 170.2, 140.8, 139.5, 131.6, 130.4, 128.4, 126.0, 118.7, 88.8, 83.0, 56.7, 50.1, 36.8, 36.5, 35.0, 31.0, 30.5, 26.0, 24.2, 18.8; HRMS (ESI) for C24H32NO4, calcd 398.2331, found 398.2328.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 2-methoxyacetate (13): yield 14%, white amorphous powder; 1H-NMR δ 6.20 (1H, d, J = 2.9 Hz), 5.47 (1H, d, J = 3.3 Hz), 5.20 (1H, d, J = 5.0 Hz), 5.16 (1H, d, J = 10.1 Hz), 3.82 (2H, s, J = 8.8 Hz), 3.12–3.09 (2H, m), 2.74–2.68 (1H, m), 2.51–2.44 (2H, m), 2.30–2.28 (4H, m), 2.14–2.10 (1H, dd, J = 13.7, 2.1 Hz), 2.00–1.92 (1H, m), 1.87–1.86 (1H, dd, J = 6.9, 1.3 Hz), 1.74 (3H, s), 1.58 (3H, s); 13C-NMR δ 171.0, 170.2, 139.5, 131.7, 130.2, 130.1, 130.0, 118.7, 88.8, 83.0, 57.1, 50.1, 36.5, 35.0, 30.5, 25.9, 24.2, 18.6; HRMS (ESI) for C18H28NO5, calcd 338.1967, found 338.1960.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl acrylate (18): yield 78%, white amorphous powder; 1H-NMR δ 6.47–6.37 (1H, dd, J = 17.3, 1.3 Hz), 6.21 (1H, d, J = 3.3 Hz), 6.13–6.06 (1H, m), 5.80–5.77 (1H, dd, J = 10.3, 1.3 Hz), 5.48 (1H, d, J = 3.1 Hz), 3.82 (2H, t, J = 8.8 Hz), 3.12–3.09 (2H, m), 2.74–2.68 (1H, m), 2.51–2.44 (2H, m), 2.30–2.28 (4H, m), 2.14–2.10 (1H, dd, J = 13.7, 2.1 Hz), 2.00–1.92 (1H, m), 1.87–1.86 (1H, dd, J = 6.9, 1.3 Hz), 1.74 (3H, s), 1.58 (3H, s); 13C-NMR δ 170.3, 165.5, 139.4, 131.7, 130.3, 130.0, 118.8, 88.8, 83.0, 57.1, 50.1, 36.5, 35.0, 30.5, 25.9, 24.2, 18.8; HRMS (ESI) for C18H26NO4, calcd 320.1862, found 320.1859.

(E)-(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl but-2-enoate (19): yield 14%, white amorphous powder; 1H-NMR δ 6.22 (1H, d, J = 3.3 Hz), 5.68 (1H, d, J = 2.8 Hz), 5.47 (1H, d, J = 10.2 Hz), 3.81 (1H, t, J = 10.2 Hz), 3.15 (1H, d, J = 10.0 Hz), 2.73–2.67 (1H, m), 2.57–2.43 (2H, m), 2.28–2.27 (3H, m), 2.15 (3H, s), 2.12–2.08 (1H, dd, J = 13.9, 2.1 Hz), 2.00–1.92 (2H, m), 1.87 (3H, s), 1.73 (3H, s), 1.59 (3H, s); 13C-NMR δ 170.3, 166.2, 155.4, 139.5,
131.5, 130.6, 118.7, 117.7, 88.2, 83.1, 57.0, 50.3, 36.8, 34.9, 30.6, 27.4, 25.9, 24.2, 20.1, 18.9; HRMS (ESI) for C_{20}H_{27}O_{4}, calcd 331.1909, found 331.1903.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl cinnamate (21): yield 23%, white amorphous powder; $^1$H-NMR δ 7.76 (1H, d, J = 16.0 Hz), 7.59–7.57 (2H, m), 7.39 (3H, d, J = 5.0 Hz), 6.45 (1H, d, J = 16.0 Hz), 6.24 (1H, d, J = 3.1 Hz), 3.88 (1H, t, J = 10.2 Hz), 3.20 (1H, d, J = 10.0 Hz), 2.78–2.73 (1H, m), 2.65–2.61 (1H, m), 2.55–2.48 (1H, m), 2.31 (3H, s), 2.16 (1H, d, J = 13.5 Hz), 2.07–1.98 (1H, q), 1.75 (3H, s), 1.63 (4H, s); $^{13}$C-NMR δ 170.4, 166.4, 144.5, 139.5, 134.7, 131.6, 130.0, 129.9, 128.8, 128.2, 119.7, 118.8, 88.7, 83.1, 57.3, 50.0, 36.7, 35.0, 30.6, 26.0, 24.2, 18.6; HRMS (ESI) for C_{24}H_{30}NO_{4}, calcd 396.2175, found 396.2167.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl hex-5-ynoate (22): yield 65%, white amorphous powder; $^1$H-NMR δ 6.21 (1H, d, J = 3.1 Hz), 5.49 (1H, d, J = 2.7 Hz), 3.82 (1H, t, J = 10.1 Hz), 3.15 (1H, d, J = 9.3 Hz), 2.91–2.82 (3H, m), 2.14–2.10 (1H, m), 2.04–2.01 (3H, m), 1.97–1.87 (8H, m), 1.83–1.75 (6H, m), 1.63 (1H, s); $^{13}$C-NMR δ 172.4, 170.2, 139.4, 131.7, 130.2, 118.8, 88.8, 83.6, 83.0, 69.0, 56.7, 50.1, 36.5, 34.9, 34.1, 30.5, 25.9, 24.2, 23.7, 18.8, 17.8; HRMS (ESI) for C_{21}H_{30}NO_{4}, calcd 396.2175, found 360.2172.

General Procedure for the Synthesis of Compounds 7, 8, and 14–16

To a mixture of MCL (99.2 mg, 0.4 mmol), NaH (20 mmol), and THF (2 mL) was added appropriate acyl chloride (12 mmol) at 0 °C. The resulting mixture was stirred at room temperature until the starting material disappeared on the TLC. The reaction mixture was diluted with water (3 mL), extracted with ethyl acetate (5 mL × 2). The organic layer was successively washed with saturated citric acid (8 mL × 3), NaHCO$_3$ (8 mL × 3), and brine (8 mL × 3), and then dried over anhydrous Na$_2$SO$_4$, concentrated under reduced pressure to give a crude residue, which was purified by silica gel column chromatography to afford the product.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl pentanoate (7): yield 38%, white amorphous powder; $^1$H-NMR δ 6.19 (1H, d, J = 3.1 Hz), 5.47 (1H, d, J = 2.9 Hz), 3.78 (1H, t, J = 10.1 Hz), 3.13 (1H, d, J = 10.0 Hz), 2.72–2.66 (1H, m), 2.49–2.42 (2H, m), 2.37–2.31 (1H, m), 2.30–2.26 (4H, m), 2.12–2.08 (1H, dd, J = 13.7, 2.2 Hz), 1.97–1.88 (1H, m), 1.75 (3H, s), 1.64–1.56 (2H, m), 1.55 (3H, s), 1.40–1.31 (3H, m), 0.92 (3H, t, J = 7.3 Hz); $^{13}$C-NMR δ 173.4, 170.2, 139.5, 131.6, 130.4, 118.7, 88.5, 83.0, 56.8, 50.2, 36.5, 35.2, 34.9, 30.5, 27.1, 25.9, 24.1, 22.2, 18.8, 13.8; HRMS (ESI) for C_{21}H_{30}NO_{4}, calcd 333.2066, found 333.2061.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl isobutyrate (8): yield 27%, white amorphous powder; $^1$H-NMR δ 6.21 (1H, d, J = 3.0 Hz), 5.48 (1H, d, J = 2.8 Hz), 3.81 (1H, t, J = 10.1 Hz), 3.15 (1H, d, J = 10.3 Hz), 2.74–2.68 (1H, m), 2.57–2.44 (3H, m), 2.30–2.29 (3H, m), 2.14–2.10 (1H, dd, J = 13.7, 2.1 Hz), 1.98–1.90 (1H, m), 1.74 (3H, s), 1.66 (1H, s), 1.56 (3H, s), 1.21–1.17 (6H, m); $^{13}$C-NMR δ 176.6, 170.2, 139.6, 131.5, 130.4, 118.6,
(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 2-chloroacetate (14): yield 56%, white amorphous powder; \(^1\)H-NMR \(\delta\) 6.23 (1H, d, \(J = 3.3\) Hz), 5.50 (1H, d, \(J = 3.1\) Hz), 4.14–4.05 (2H, m), 3.81 (1H, t, \(J = 10.1\) Hz), 3.20 (1H, d, \(J = 10.0\) Hz), 2.74–2.68 (1H, m), 2.54–2.47 (2H, m), 2.30–2.29 (3H, m), 2.15–2.11 (1H, dd, \(J = 13.8, 2.3\) Hz), 2.07–1.97 (1H, m), 1.75 (3H, s), 1.62 (4H, s); \(^{13}\)C-NMR \(\delta\) 170.1, 166.4, 139.2, 132.1, 129.8, 119.0, 90.8, 82.8, 56.4, 50.1, 42.0, 36.3, 35.0, 30.3, 25.9, 24.2, 18.8; HRMS (ESI) for C\(_{19}\)H\(_{30}\)NO\(_4\), calcd 336.2175, found 336.2172.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 2,2-dichloroacetate (15): yield 21%, white amorphous powder; \(^1\)H-NMR \(\delta\) 6.23 (1H, d, \(J = 3.3\) Hz), 5.96 (1H, s), 5.51 (1H, d, \(J = 3.0\) Hz), 3.81 (1H, t, \(J = 10.1\) Hz), 3.21 (1H, d, \(J = 10.1\) Hz), 2.76–2.70 (1H, m), 2.56–2.48 (2H, m), 2.30 (3H, s), 2.15–2.11 (1H, dd, \(J = 13.8, 2.3\) Hz), 2.07–1.99 (1H, m), 1.75 (3H, s), 1.66 (4H, s); \(^{13}\)C-NMR \(\delta\) 169.9, 163.4, 139.2, 132.4, 129.5, 119.0, 92.3, 82.5, 65.2, 56.5, 50.1, 34.9, 30.2, 25.9, 24.1, 18.6; HRMS (ESI) for C\(_{17}\)H\(_{25}\)Cl\(_2\)NO\(_4\), calcd 376.1082, found 376.1078.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 2-bromoacetate (16): yield 46%, white amorphous powder; \(^1\)H-NMR \(\delta\) 6.22 (1H, d, \(J = 3.3\) Hz), 5.49 (1H, d, \(J = 3.0\) Hz), 3.86 (2H, s), 3.80 (1H, d, \(J = 10.1\) Hz), 2.74–2.68 (1H, m), 2.53–2.46 (2H, m), 2.30–2.29 (3H, m), 2.14–2.10 (1H, dd, \(J = 13.8, 2.3\) Hz), 2.06–1.94 (1H, m), 1.74 (3H, s), 1.71 (1H, s), 1.60 (3H, s); \(^{13}\)C-NMR \(\delta\) 170.1, 166.3, 139.3, 132.1, 129.9, 118.9, 90.8, 82.8, 56.5, 50.1, 36.2, 34.9, 30.3, 27.7, 25.9, 24.2, 18.7; HRMS (ESI) for C\(_{17}\)H\(_{25}\)BrNO\(_4\), calcd 386.0967, found 386.0963.

**General Procedure for the Synthesis of Compounds 11 and 12**

A mixture of MCL (99.2 mg, 0.4 mmol), appropriate carboxylic acid (4 mmol), EDCI (2.4 g, 12.5 mmol), DMAP (488 mg, 4 mmol), and CH\(_2\)Cl\(_2\) (10 mL) was refluxed until the starting material disappeared on the TLC. The reaction mixture was diluted with water (15 mL), and then extracted with CH\(_2\)Cl\(_2\) (10 mL \(\times 2\)). The organic layer was successively washed with saturated citric acid (10 mL \(\times 3\)), NaHCO\(_3\) (10 mL \(\times 3\)), and brine (10 mL \(\times 2\)), and then dried over anhydrous Na\(_2\)SO\(_4\), concentrated under reduced pressure to give a crude residue, which was purified by silica gel column chromatography to afford the product.
13C-NMR δ 171.5, 169.2, 138.4, 130.7, 129.2, 117.7, 87.7, 82.0, 55.7, 50.1, 49.1, 35.5, 34.0, 33.9, 29.4, 27.2, 24.9, 23.1, 21.2, 17.8; HRMS (ESI) for C20H28N3O4, calcd 374.2080, found 374.2077.

(3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl pent-4-enoate (12): yield 53%, white amorphous powder; 1H-NMR (400 MHz, CDCl3) δ 6.18 (1H, d, J = 3.2 Hz), 5.87–5.80 (1H, m), 5.46 (1H, d, J = 3.0 Hz), 5.09 (1H, d, J = 16.9 Hz), 5.00 (1H, d, J = 9.6 Hz), 3.80–3.74 (1H, m), 3.12 (1H, d, J = 7.4 Hz), 2.68 (1H, s), 2.45–2.40 (3H, m), 2.37 (4H, s), 2.25 (3H, s), 2.11–2.07 (1H, m), 1.95–1.89 (1H, m), 1.71 (3H, s), 1.54 (3H, d, J = 3.8 Hz); 13C-NMR (100 MHz, CDCl3) δ 172.4, 170.2, 139.5, 136.9, 131.6, 130.3, 118.7, 115.3, 88.7, 82.9, 56.7, 50.1, 36.5, 35.0, 34.6, 30.4, 29.0, 25.9, 24.2, 18.8; HRMS (ESI) for C20H27O4, calcd 331.1909, found 331.1910.

Synthesis of (3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 5-bromopentanoate (17)

A mixture of MCL (99.2 mg, 0.4 mmol), 5-bromopentanoic acid (216.0 mg, 1.2 mmol), Sc(OTf)3 (118.1 mg, 0.24 mmol), DMAP (293.2 mg, 2.4 mmol), and CH2Cl2 (10 mL) was stirred at –8 °C for 30 min. To the resulting mixture was added DIPC (302.9 mg, 2.4 mmol). The reaction mixture was stirred at room temperature for 2 h, diluted with water (10 mL), and extracted with CH2Cl2 (10 mL × 2). The organic layer was successively washed with saturated citric acid (10 mL × 3), NaHCO3 (10 mL × 3), and brine (10 mL × 2), and then dried over anhydrous Na2SO4, concentrated under reduced pressure to give a crude residue, which was purified by silica gel column chromatography to afford compound 17 (42.8 mg, yield 25.8%). 1H-NMR δ 6.22 (1H, d, J = 3.2 Hz), 5.49 (1H, d, J = 2.8 Hz), 3.81 (1H, t, J = 10.2 Hz), 3.47 (2H, t, J = 6.5 Hz), 3.15 (1H, d, J = 10.0 Hz), 2.73–2.68 (1H, m), 2.51–2.44 (2H, m), 2.40–2.32 (2H, m), 2.30 (2H, d, J = 6.4 Hz), 2.14–2.10 (1H, dd, J = 13.7, 1.9 Hz), 1.99–1.91 (3H, m), 1.83–1.78 (2H, m), 1.74 (3H, s), 1.60 (3H, s), 1.57 (2H, s); 13C-NMR δ 172.5, 170.2, 139.4, 131.7, 130.2, 118.8, 88.75, 83.0, 56.7, 50.1, 36.5, 35.0, 34.5, 33.5, 32.0, 30.5, 25.9, 24.2, 23.6, 18.8; HRMS (ESI) for C20H27BrNO4, calcd 428.1436, found 428.1437.

Synthesis of (3aS,9R,9aS,9bS)-6,9-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-9-yl 4-(1-(hydroxymethyl)-1H-1,2,3-triazol-4-yl)butanoate (23)

To a solution of compound 22 (200 mg, 0.58 mmol), 6-azidohexan-1-ol (125.4 mg, 0.88 mmol), sodium ascorbate (463 mg, 2.3 mmol), copper sulfate (146 mg, 0.58 mmol) in mixed solvent (tert-butyl alcohol/water = 1:1) 3 mL under N2 atmosphere. The resulting mixture was stirred for 2 h at room temperature. The reaction mixture was poured into ice water (5 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layer was washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure to give a crude residue, which was purified with chromatography to afford compound 23 (120 mg, yield 61%). 1H-NMR δ 7.52 (1H, s), 6.20 (1H, d, J = 3.3 Hz), 5.49 (1H, d, J = 3.0 Hz), 4.34 (2H, t, J = 7.1 Hz), 3.81 (1H, t, J = 10.2 Hz), 3.63 (2H, t, J = 6.4 Hz), 3.14 (1H, d, J = 10.1 Hz), 2.81–2.76 (2H, m), 2.74–2.67 (1H, m), 2.51–2.43 (2H, m), 2.39–2.31 (2H, m), 2.29–2.27 (4H, m), 2.13–2.09 (1H, dd, J = 13.8, 2.3 Hz), 2.05–2.00 (3H, m), 1.97–1.88 (5H, m), 1.72 (4H, s), 1.60–1.53 (6H, m); 13C-NMR δ 172.6, 170.2, 147.1, 139.4, 131.7.
130.0, 121.3, 118.8, 88.6, 83.1, 62.2, 56.7, 50.0, 49.9, 34.9, 32.3, 30.4, 30.1, 26.1, 25.8, 25.1, 24.8, 24.7, 24.1, 18.8; HRMS (ESI) for C$_{27}$H$_{40}$N$_{3}$O$_{5}$, calcd 486.2968, found 486.2968.

### 3.3. Biological assay for Activity of Compounds 1–23

The cell viability assay was carried out using the well documented MTT method. All the tested cells were cultured with drugs for 72 hours before adding the MTT reagent. All the experiments were carried out as triplicated and we tested every compound for three times.

### 4. Conclusions

In summary, a series of MCL derivatives 2–23 were synthesized and assayed for their activities against the cultured AML cell line HL-60 and doxorubicin-resistant cell line HL-60/A. Compounds 7, 9, 13, 16, 18, and 22 were selected to test their inhibitory activity against AML KG-1a progenitor cells. Our investigation demonstrated that simple modifications of hydroxyl at the C4 position of MCL can maintain comparable activities against regular AML cell lines HL-60 and HL-60/A, and the progenitor cell line KG-1a. Based on the above results, the following conclusions could be made: (a) suitable etherification of hydroxyl group at the C4 position was found to retain anti-AML activities; (b) acylation of the hydroxyl group at the C4 position generally maintained activities against HL-60, HL-60/A, and KG-1a cell lines; (c) additional alkylating groups appear to enhance anti-AML activity; (d) the steric effects in the introduced conjugated ester groups play a role to the anti-AML activities.

Most importantly, KG-1a is a multi-drug resistant (MDR) cell lines, and many drugs demonstrated significant lower activities against KG-1a [19–21]. For example, doxorubicin showed 20-fold reduced activity against KG-1a vs. against HL-60 (Table 1), while our selected compounds 7, 9, 13, 16, 18, and 22 maintained significant activities against KG-1a (only 1.1–2.7 fold reduction). Moreover, MCL can selectively inhibit AML stem and progenitor cells [11], but the mechanisms responsible for the effects of MCL are still unclear. On the basis of our established structure-activity relationships, we may conclude that the hydroxyl group at C4 of MCL might be a suitable position for the design and synthesis of appropriate molecular probes to explore the specific targets of KG-1a progenitor cells and stem cells. Synthesis and application of molecular probes are in progress in our laboratory, and the results will be reported in due course.

### Acknowledgments

This work was supported by the National Natural Science Foundation of China (NSFC) (No. 81001377 to Q.Z. and No. 21072106 to Y.C.), Fok Ying Tong Education Foundation (No. 122037).

### Conflict of Interest

The authors declare no conflict of interest.
References

1. Barth, B.M.; Altinoğlu, E.I.; Shanmugavelandy, S.S.; Kaiser, J.M.; Crespo-Gonzalez, D.; DiVittore, N.A.; McGovern, C.; Goff, T.M.; Keasey, N.R.; Adair, J.H.; et al. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. *ACS Nano* 2011, 5, 5325–5327.

2. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat. Med.* 1997, 3, 730–737.

3. Blair, A.; Hogge, D.E.; Sutherland, H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71−/HLA-DR−. *Blood* 1998, 92, 4325–4335.

4. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. *Nature* 1994, 367, 645–648.

5. She, M.; Niu, X.; Chen, X.; Li, J.; Zhou, M.; He, Y.; Le, Y.; Guo, K. Resistance of leukemic stem-cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. *Cancer Lett.* 2012, 318, 173–179.

6. Jawad, M.; Seedhouse, C.; Mony, U.; Grundy, M.; Russell, N.H.; Pallis, M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia sensitivity to mylotarg by stem cells in AML. *Leukemia* 2010, 24, 74–80.

7. Guzman, M.L.; Rossi, R.M.; Karnischky, L.; Li, X.; Peterson, D.R.; Howard, D.S.; Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood* 2005, 105, 4163–4169.

8. Guzman, M.L.; Rossi, R.M.; Neelakantan, S.; Li, X.; Corbett, C.A.; Hassane, D.C.; Becker, M.W.; Bennett, J.M.; Sullivan, E.; Lachowicz, J.L.; et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood* 2007, 110, 4427–4435.

9. Neelakantan, S.; Nasim, S.; Guzman, M.L.; Jordan, C.T.; Crooks, P.A. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). *Bioorg. Med. Chem. Lett.* 2009, 19, 4346–4349.

10. Kevin, P. New agents for the treatment of leukemia: Discovery of DMAPT (LC-1). *Drug Discov. Today* 2010, 15, 322.

11. Zhang, Q.; Lu, Y.; Ding, Y.; Zhai, J.; Ji, Q.; Ma, W.; Yang, M.; Fan, H.; Long, J.; Tong, Z.; et al. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. *J. Med. Chem.* 2012, 55, 8757–8769.

12. Schall, A.; Reiser, O. Synthesis of biologically active guaianolides with a trans-annulated lactone moiety. *Eur. J. Org. Chem.* 2008, 2008, 2353–2364.

13. Ogura, M.; Cordell, G.A.; Farnsworth, N.R. Anticancer sesquiterpene lactones of *Michelia compressa* (magnoliaceae). *Phytochemistry* 1978, 17, 957–961.

14. Jacobsson, U.; Kumar, V.; Saminathan, S. Sesquiterpene lactones from *Michelia champaca*. *Phytochemistry* 1995, 39, 839–843.
15. Zhai, J.-D.; Li, D.; Long, J.; Zhang, H.-L.; Lin, J.-P.; Qiu, C.-J.; Zhang, Q.; Chen, Y. Biomimetic semisynthesis of arglabin from parthenolide. *J. Org. Chem.* **2012**, *77*, 7103–7107.
16. Kupchan, S.M.; Eakin, M.A.; Thomas, A.M. Tumor inhibitors. 69. Structure-cytotoxicity relations among the sesquiterpene lactones. *J. Med. Chem.* **1971**, *14*, 1147–1152.
17. Lee, K.-H.; Meck, R.; Piantadosi, C.; Huang, E.-S. Antitumor agents. 4. Cytotoxicity and *in vivo* activity of helenalin esters and related derivatives. *J. Med. Chem.* **1973**, *16*, 299–301.
18. Zhao, H.; Pendri, A.; Greenwald, R.B. General procedure for acylation of 3° alcohols: Scandium triflate/DMAP reagent. *J. Org. Chem.* **1998**, *63*, 7559–7562.
19. Banker, D.E.; Cooper, J.J.; Fennell, D.A.; Willman, C.L.; Appelbaum, F.R.; Cotter, F.E. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. *Leukemia Res.* **2002**, *26*, 91–106.
20. Soligo, D.; Servida, F.; Delia, D.; Fontanella, E.; Lamorte, G.; Caneva, L.; Fumiatti, R.; Deliliers, G.L. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. *Br. J. Haematol.* **2001**, *113*, 126–135.
21. Bailly, J.D.; Muller, C.; Jaffrézou, J.P.; Demur, C.; Gassar, G.; Bordier, C.; Laurent, G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. *Leukemia* **1995**, *9*, 799–807.

*Sample Availability*: Samples of all compounds are available from the authors.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).